Photo: Michael Ciaglo / Getty Images
Johnson & Johnson announced Tuesday that its COVID-19 vaccine is 94% effective when a booster is given a few months later. of the original dose.
The Johnson & Johnson single shot vaccineThe company said in a statement, it has worked well in real patient studies, offers long-lasting protection against the virus, and boosts the immune system.
When a booster was given two months after the first dose, the company said the vaccine was 100% effective in protecting recipients from severe COVID-19 and was 75% effective in preventing symptomatic COVID-19 worldwide.
It was 94% effective in preventing symptomatic COVID-19 in the United States, based on data presented.
The pharmaceutical company made the announcement in a publication of late-stage clinical data for adenovirus-based vaccine, produced by Janssen, the Johnson & Johnson subsidiary, which received emergency use authorization in the United States earlier this year.
Johnson & Johnson said it conducted two studies in which volunteers received a second dose of vaccine between two and six months after the first.
The boost led to an increase in the immune response in recipients between 18 and 55 years of age.
“When a Johnson & Johnson COVID-19 vaccine booster was administered two months after the first injection, antibody levels rose four to six times higher than those seen after the single injection,” the pharmacist noted in a release.
In another study that tested a booster dose after six months, Johnson & Johnson said it observed nine to 12 times higher antibody increases in recipients.
The company also noted that one dose of the vaccine was shown to be 79% effective against infection in the United States between March and the end of July, and 81% effective at preventing hospitalization.
“There was no evidence of reduced effectiveness for the duration of the study, even as the Delta variant became dominant in the US,” he noted.
“Our single-shot vaccine generates strong immune responses and long-lasting immune memory, and when a Johnson & Johnson COVID-19 vaccine booster is given, the strength of protection against COVID-19 is further increased.“Janssen’s global director said in a statement. Research and Development, Dr. Mathai Mammen.
Johnson & Johnson reported that it is in talks with US and European regulators about possible booster doses.
Last week, the Food and Drug Administration recommended a Pfizer Booster Vaccine in Americans 65 Years and Older and those most at risk.
It may interest you
Monoclonal antibodies, the popular alternative against COVID-19 for those who do not want to be vaccinated
Moderna and Novavax are already working on a vaccine that combines COVID-19 and influenza in a single injection
Modern vaccine protection against COVID-19 lasts at least 6 months without needing booster